Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C22H31N3O5 · H2O
CAS Number:
Molecular Weight:
435.51
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
SMILES string
N21N(CCC[C@H]2C(=O)O)CCC[C@@H](C1=O)N[C@@H](CCc3ccccc3)C(=O)OCC.O
InChI
1S/C22H31N3O5.H2O/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26;/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28);1H2/t17-,18-,19-;/m0./s1
InChI key
JQRZBPFGBRIWSN-YOTVLOEGSA-N
grade
pharmaceutical primary standard
API family
cilazapril
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Related Categories
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Cilazapril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
[The study of the effect of Cilazapril and valsartan on angiotensin 1 and angiotensin 2 receptors mRNA expression and myocardial interstitial collagen metabolism after myocardial infarction in rats].
Shi-shu Zhang et al.
Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue, 20(4), 240-241 (2008-04-19)
Leszek Tylicki et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 52(3), 486-493 (2008-04-22)
Agents inhibiting the renin-angiotensin-aldosterone (RAAS) system have an important role in slowing the progression of chronic kidney disease. We evaluated the hypothesis that the addition of an aldosterone receptor antagonist to an angiotensin-converting enzyme (ACE) inhibitor and angiotensin II type
Shih-Hsien Sung et al.
Journal of the Chinese Medical Association : JCMA, 71(5), 247-253 (2008-05-21)
Combined regimen may be superior to monotherapy in blood pressure (BP) control. Since BP control is critically related to cardiovascular mortality and morbidity in hypertensive patients, this study aimed to evaluate the efficacy and safety of a low-dose combined regimen
How controlling of hypertension might matter.
Kazuo Hara et al.
Circulation journal : official journal of the Japanese Circulation Society, 73(12), 2208-2209 (2009-11-27)
Leszek Tylicki et al.
Scandinavian journal of urology and nephrology, 42(4), 381-388 (2009-02-21)
Despite the proven effectiveness of combination therapy with an angiotensin I-converting enzyme inhibitor (ACEI) and angiotensin II-receptor blockers (ARBs) for the prevention and treatment of kidney disease, it has not proved possible to inhibit the progress of chronic nephropathies completely.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service